Oncorus Stock Forecast, Price & News

-0.02 (-0.20 %)
(As of 09/16/2021 03:15 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume580 shs
Average Volume146,800 shs
Market Capitalization$256.20 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ONCR News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncorus and its competitors with MarketBeat's FREE daily newsletter.

Oncorus logo

About Oncorus

Oncorus, Inc., a clinical stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. Oncorus, Inc. has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.20 out of 5 stars

Medical Sector

352nd out of 1,352 stocks

Pharmaceutical Preparations Industry

170th out of 665 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Oncorus (NASDAQ:ONCR) Frequently Asked Questions

Is Oncorus a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oncorus in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Oncorus stock.
View analyst ratings for Oncorus
or view top-rated stocks.

What stocks does MarketBeat like better than Oncorus?

Wall Street analysts have given Oncorus a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Oncorus wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Oncorus?

Oncorus saw a decline in short interest in August. As of August 13th, there was short interest totaling 739,800 shares, a decline of 30.9% from the July 29th total of 1,070,000 shares. Based on an average trading volume of 124,900 shares, the short-interest ratio is presently 5.9 days. Currently, 3.9% of the shares of the stock are short sold.
View Oncorus' Short Interest

When is Oncorus' next earnings date?

Oncorus is scheduled to release its next quarterly earnings announcement on Wednesday, November 10th 2021.
View our earnings forecast for Oncorus

How were Oncorus' earnings last quarter?

Oncorus, Inc. (NASDAQ:ONCR) posted its quarterly earnings data on Wednesday, August, 4th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by $0.04.
View Oncorus' earnings history

What price target have analysts set for ONCR?

4 analysts have issued 12 month price targets for Oncorus' stock. Their forecasts range from $22.00 to $40.00. On average, they anticipate Oncorus' share price to reach $33.00 in the next twelve months. This suggests a possible upside of 229.3% from the stock's current price.
View analysts' price targets for Oncorus
or view top-rated stocks among Wall Street analysts.

Who are Oncorus' key executives?

Oncorus' management team includes the following people:
  • Dr. Mitchell H. Finer, Co-Founder & Exec. Chairman (Age 62, Pay $126.65k)
  • Dr. Theodore T. Ashburn, Pres, CEO & Director (Age 54, Pay $760.13k)
  • Mr. Stephen Harbin, COO & Chief of Staff (Age 62, Pay $815.09k)
  • Dr. Christophe Queva Ph.D., Chief Scientific Officer & Sr. VP of Research (Age 53, Pay $545.58k) (LinkedIn Profile)
  • Mr. John McCabe M.B.A., CFO, Treasurer & Sec. (Age 51)
  • Dr. John Mayer Goldberg M.D., Sr. VP of Clinical Devel. (Age 47)

Who are some of Oncorus' key competitors?

What other stocks do shareholders of Oncorus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncorus investors own include Cronos Group (CRON), Deere & Company (DE), GrowGeneration (GRWG), Immunomedics (IMMU), Teck Resources (TECK), Abbott Laboratories (ABT), Ability (ABIL), AbbVie (ABBV), Axon Enterprise (AAXN) and Atlas Air Worldwide (AAWW).

When did Oncorus IPO?

(ONCR) raised $87 million in an IPO on Friday, October 2nd 2020. The company issued 5,800,000 shares at $14.00-$16.00 per share. Jefferies, Evercore ISI and Piper Sandler acted as the underwriters for the IPO.

What is Oncorus' stock symbol?

Oncorus trades on the NASDAQ under the ticker symbol "ONCR."

Who are Oncorus' major shareholders?

Oncorus' stock is owned by a variety of institutional and retail investors. Top institutional investors include Citadel Advisors LLC (7.38%), CHI Advisors LLC (6.74%), Perceptive Advisors LLC (5.68%), BlackRock Inc. (4.30%), Sphera Funds Management LTD. (3.47%) and Vanguard Group Inc. (2.58%). Company insiders that own Oncorus stock include Christophe Queva, Ernest C Garcia II, Luke Evnin and Sunstates Fund LP Mpm.
View institutional ownership trends for Oncorus

Which major investors are selling Oncorus stock?

ONCR stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Morgan Stanley, Morgan Stanley, CHI Advisors LLC, PNC Financial Services Group Inc., Sphera Funds Management LTD., and Bank of America Corp DE. Company insiders that have sold Oncorus company stock in the last year include Christophe Queva, and Ernest C Garcia II.
View insider buying and selling activity for Oncorus
or view top insider-selling stocks.

Which major investors are buying Oncorus stock?

ONCR stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Deutsche Bank AG, Vanguard Group Inc., State Street Corp, Geode Capital Management LLC, We Are One Seven LLC, Nuveen Asset Management LLC, and Northern Trust Corp. Company insiders that have bought Oncorus stock in the last two years include Luke Evnin, and Sunstates Fund LP Mpm.
View insider buying and selling activity for Oncorus
or or view top insider-buying stocks.

How do I buy shares of Oncorus?

Shares of ONCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Oncorus' stock price today?

One share of ONCR stock can currently be purchased for approximately $10.02.

How much money does Oncorus make?

Oncorus has a market capitalization of $258.00 million. The company earns $-48,300,000.00 in net income (profit) each year or ($9.35) on an earnings per share basis.

How many employees does Oncorus have?

Oncorus employs 56 workers across the globe.

What is Oncorus' official website?

The official website for Oncorus is

How can I contact Oncorus?

The company can be reached via phone at 857-320-6400 or via email at [email protected]

This page was last updated on 9/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.